Trial · NCT01549977
Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable Angina
NCT01549977, Phase 2, Terminated, Takeda; results first posted 2013-12-20
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable Angina. Trials, record NCT01549977. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01549977
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable Angina
- NCT number
- NCT01549977
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- Takeda
- Conditions
- Angina
- Interventions
- Febuxostat, Placebo
- First posted
- 2012-03-09
- Last updated
- 2013-12-20
- Results first posted
- 2013-12-20
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Exercise Treadmill Testing (ETT) Duration at Week 12 | Baseline and Week 12 | The change between the duration of ETT at Week 12 relative to Baseline. ETTs were conducted using the modified Bruce Protocol. Participants exercised on a treadmill, starting at 1.7 mph and 0% incline. The intensity of exercise (speed and/or incline) was increased at 3 minute intervals. |
| Secondary | Change From Baseline in Time to Onset of Angina During ETT at Week 12 | Baseline and Week 12 | The change between the time to onset of angina during the exercise treadmill test (ETT) at Week 12 relative to Baseline. |
| Secondary | Change From Baseline in Time to Onset of ≥1 mm ST-segment Depression During ETT at Week 12 | Baseline and Week 12 | The change between the time to onset of ≥1 mm ST-segment depression during exercise treadmill test (ETT) at Week 12 relative to Baseline. ST-segment is measured by electrocardiography (ECG) and represents the interval between ventricular depolarization and repolarization. |
| Secondary | Change From Baseline in Maximum ST-segment Depression During ETT at Week 12 | Baseline and Week 12 | The change between the maximum ST-segment depression during ETT at Week 12 relative to Baseline. ST-segment is measured by electrocardiography (ECG) and represents the interval between ventricular depolarization and repolarization. |
| Secondary | Percentage of Participants Stopping ETT Due to Angina at Week 12 | Week 12 | The percentage of participants who had to stop exercise treatment testing (ETT) due to experiencing angina symptoms at Week 12. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Exercise Treadmill Testing (ETT) Duration at Week 12 | Baseline and Week 12 | This analysis was not performed since only one participant completed the study prior to study termination. | ||
| SECONDARY | Change From Baseline in Time to Onset of Angina During ETT at Week 12 | Baseline and Week 12 | This analysis was not performed since only one participant completed the study prior to study termination. | ||
| SECONDARY | Change From Baseline in Time to Onset of ≥1 mm ST-segment Depression During ETT at Week 12 | Baseline and Week 12 | This analysis was not performed since only one participant completed the study prior to study termination. | ||
| SECONDARY | Change From Baseline in Maximum ST-segment Depression During ETT at Week 12 | Baseline and Week 12 | This analysis was not performed since only one participant completed the study prior to study termination. | ||
| SECONDARY | Percentage of Participants Stopping ETT Due to Angina at Week 12 | Week 12 | This analysis was not performed since only one participant completed the study prior to study termination. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Febuxostat 80 mg | 1 | |
| Overall Study | STARTED | Placebo | 0 | |
| Overall Study | COMPLETED | Febuxostat 80 mg | 1 | |
| Overall Study | COMPLETED | Placebo | 0 | |
| Overall Study | NOT COMPLETED | Febuxostat 80 mg | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Blood creatinine increased | Investigations | Febuxostat 80 mg | 1 | 1 | |
| other | Blood creatinine increased | Investigations | Placebo | 0 | 0 | |
| other | Urinary sediment present | Investigations | Febuxostat 80 mg | 1 | 1 | |
| other | Urinary sediment present | Investigations | Placebo | 0 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Febuxostat 80 mg | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Febuxostat 80 mg | 1 | 1 |
| Total, other adverse events | Placebo | 0 | 0 |
| Total, serious adverse events | Febuxostat 80 mg | 0 | 1 |
| Total, serious adverse events | Placebo | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01549977
GET https://conductscience.org/api/trials/v1/NCT01549977/registered